전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
leucaféresis
leukapheresis
마지막 업데이트: 2014-12-09
사용 빈도: 11
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
en otras circunstancias, se recomienda la realización de leucaféresis adicionales.
in other circumstances, additional leukaphereses are recommended.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
en otras circunstancias, puede ser necesaria la realización de leucaféresis adicionales.
in other circumstances, additional leukaphereses may be necessary.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
la administración de filgrastim debe mantenerse hasta la realización de la última leucaféresis.
filgrastim dosing should be maintained until the last leukapheresis.
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
no deben realizarse leucaféresis a donantes tratados con anticoagulantes o que se sepa que tengan defectos en la homeostasis.
leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
se debe realizar la leucaféresis en el período comprendido entre el aumento de ran de 5,0 x 109/l.
leukapheresis should be performed during the period when the anc rises from 5.0 x 109/l.
마지막 업데이트: 2012-04-10
사용 빈도: 4
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
entre ellos, se comunicaron dos casos con plaquetas < 50 x 109/l que se atribuyeron al procedimiento de leucaféresis.
among these, two cases of platelets < 50 x 109/l were reported and attributed to the leukapheresis procedure.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
las leucaféresis deben iniciarse en el día 5 y, si fuera necesario, continuar el día 6 con objeto de obtener 4 x 106 células cd34+/kg de peso del receptor.
leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 cd34+ cells/kg recipient bodyweight.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
el empleo de filgrastim para la movilización de pbpc en donantes sanos previo al trasplante alogénico de pbpc, permite obtener 4 x 106 células cd34+ por kilo de peso del receptor en la mayoría de los donantes después de dos leucaféresis.
prior to allogeneic pbpc transplantation, use of filgrastim for the mobilisation of pbpc in normal donors allows a collection of 4 x 106 cd34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
se ha observado leucocitosis (leucocitos > 50 x 109/l) en el 41% de los donantes y trombocitopenia transitoria (plaquetas < 100 x 109/l) después de la administración de filgrastim y los procesos de leucaféresis en el 35% de los donantes.
leukocytosis (wbc > 50 x 109/l) was observed in 41 % of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35 % of donors.
마지막 업데이트: 2017-04-26
사용 빈도: 4
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다